Skip to main content
. 2020 Nov 2;70(8):1469–1478. doi: 10.1136/gutjnl-2020-321996

Table 4.

Risk factors associated with metachronous advanced neoplasia

Risk factors at randomisation 2-examination group (n=701) 1-examination group (n=763) Both groups (n=1464)
No (%) with AN*/No Pts OR (95% CI) No (%) with AN/No Pts OR (95% CI) No (%) with AN/No Pts OR (95% CI)
No of adenomas† 2.25 (0.55 to 8.35) 3.58 (1.15 to 11.11) 2.84 (1.37 to 5.91)
1–2 6/343 (1.7) 5/395 (1.3) 11/738 (1.5)
3–4 1/187 (0.5) 3/197 (1.5) 4/384 (1.0)
≥5 5/171 (2.9) 8/171 (4.7) 13/342 (3.8)
Size of largest adenoma‡ 1.59 (0.39 to 5.87) 2.25 (0.72 to 6.96) 1.94 (0.84 to 4.40)
Small (≤5 mm) 5/246 (2.0) 5/262 (1.9) 10/508 (2.0)
Medium (6–9 mm) 2/236 (0.8) 3/263 (1.1) 5/499 (1.0)
Large (≥10 mm) 5/219 (2.3) 8/238 (3.4) 13/457 (2.8)
Morphology§
Polypoid (≥10 mm) 1.08 (0.19 to 4.38) 1.06 (0.25 to 3.55) 1.06 (0.38 to 2.63)
Absent 9/535 (1.7) 12/580 (2.1) 21/1115 (1.9)
Present 3/166 (1.8) 4/183 (2.2) 7/349 (2.0)
Flat (<10 mm) 0.99 (0.26 to 4.54) 3.04 (1.01 to 12.11)
Absent 4/232 (1.7) 0/255 (0) 4/487 (0.8)
Present 8/469 (1.7) 16/508 (3.1) 24/977 (2.5)
Depressed 2.55 (0.06 to 18.34) 1.63 (0.04 to 10.52)
Absent 12/688 (1.7) 15/743 (2.0) 27/1431 (1.9)
Present 0/13 (0) 1/20 (5.0) 1/33 (3.0)
LST-G 1.60 (0.36 to 11.57) 0.77 (0.02 to 4.84)
Absent 11/663 (1.7) 16/734 (2.2) 27/1397 (1.9)
Present 1/38 (2.6) 0/29 (0) 1/67 (1.5)
LST-NG 3.04 (0.07 to 22.84) 10.16 (2.59 to 33.84) 6.61 (2.11 to 17.61)
Absent 11/680 (1.6) 11/726 (1.5) 22/1406 (1.6)
Present 1/21 (4.8) 5/37 (13.5) 6/58 (10.3)
Pathologically advanced adenomas¶ 1.20 (0.30 to 4.45) 2.81 (0.91 to 9.50) 1.92 (0.92 to 4.00)
Absent 7/439 (1.6) 6/475 (1.3) 13/914 (1.4)
Present 5/262 (1.9) 10/288 (3.5) 15/550 (2.7)
Large serrated lesion (≥10 mm, Rt-sided**)
Absent 12/693 (1.7) 16/755 (2.1) 28/1448 (1.9)
Present 0/8 (0) 0/8 (0) 0/16 (0)
Age 1.18 (0.32 to 4.76) 2.88 (0.86 to 12.36) 1.88 (0.86 to 4.13)
<60 years 5/320 (1.6) 4/370 (1.1) 9/690 (1.3)
≥60 years 7/381 (1.8) 12/393 (3.1) 19/774 (2.5)
Gender 1.01 (0.27 to 4.63) 1.67 (0.50 to 7.16) 1.32 (0.56 to 3.00)
Female 4/235 (1.7) 4/271 (1.5) 8/506 (1.6)
Male 8/466 (1.7) 12/492 (2.4) 20/958 (2.1)
Family history of CRC†† 2.78 (0.60 to 10.59) 2.23 (0.51 to 7.55) 2.39 (1.07 to 5.35)
Absent 8/592 (1.4) 12/662 (1.8) 20/1254 (1.6)
Present 4/109 (3.7) 4/101 (4.0) 8/210 (3.8)

*Any lesion with low-grade dysplasia ≥10 mm, high-grade dysplasia.

†OR; number of adenomas (≥5 vs ≤4).

‡OR; size of largest adenoma (≥10 mm vs ≤9 mm).

§Polypoid; 0-Ip, 0-Isp, 0-Is type, Flat; 0-IIa type, Depressed; 0-IIa+IIc, 0-IIc type.

¶Any low-grade dysplasia ≥10 mm, high-grade dysplasia.

**Caecum, ascending colon, transverse colon.

††First-degree relatives.

CRC, colorectal cancer; LST-G, laterally spreading tumour, granular type; LST-NG, laterally spreading tumour, non-granular type.